Performance of an Optimized Methylation-Protein Multi-Cancer Early Detection (MCED)
Test Classifier

Vladimir G. Gainullin,[1] Melissa Gray, [1] Madhav Kumar,[1] Stephen Luebker,[1] Amy M. Lehman,[1]
Omair A. Choudhry,[1] Julia Roberta,[1] Darl D. Flake II,[1] Avinash Shanmugam,[1] Kevin Cortes,[1]
Emily Chang,[1*] Philip J. Uren,[2] Amin Mazloom,[2] Jorge Garces,[2] Gerard A. Silvestri,[3] David W.
Chesla,[4] Robert W. Given,[5] Tomasz M. Beer,[1] Frank Diehl[2**]

8
[1]Exact Sciences Corporation, Madison, WI, USA
[2]Exact Sciences Corporation, La Jolla, CA, USA
[3]Medical University of South Carolina, Charleston, SC, USA
[4]Corewell Health, Grand Rapids, MI, USA
[5]Urology of Virginia, Virginia Beach, VA, USA
*Former exact Sciences employee
15
16
**Corresponding Author
Frank Diehl, PhD
Senior Vice President, Research & Development, Multi-cancer Early Detection
Exact Sciences Corporation
11085 N. Torrey Pines Rd.
La Jolla, CA 92037
Email: fdiehl@exactsciences.com
24
25
26 **Short title** Multi-cancer early detection biomarkers in plasma
27
28 **Keywords** Multi-cancer early detection, circulating tumor DNA (ctDNA), methylation, proteins,
29 machine learning
30

Abstract

Multi-cancer early detection (MCED) tests can detect several cancer types and stages. We

previously developed a methylation and protein (MP V1) MCED classifier. In this study, we

present a refined MP V2 classifier, developed by evaluating model architectures that improved

performance in prospectively enrolled case-control cohorts under standard testing conditions.

The newly developed MP V2 classifier was trained to be more generalizable and achieve

increased early-stage sensitivity at a target specificity of ≥97.0%. MP V1 and MP V2 classifier

performances were compared using a previously described test set, and MP V2 performance

was also evaluated in a new independent clinical validation set. Compared to MP V1, the MP V2

classifier demonstrated a 7.3% increase in overall sensitivity, with sensitivity increases of 7.6%,

9.2%, and 8.3% for stages I, II, and stages I/II, respectively, in the intended use (breast and

prostate cancers excluded) test set. In an independent validation intended use set, the MP V2

classifier showed an overall sensitivity of 55.6%, with sensitivities of 26.8%, 42.9%, and 34.8%

for stages I, II, and stages I/II, respectively. In a case-control setting, the MP V2 classifier

offered improved sensitivity for early-stage cancers at a lower specificity target.

Introduction

48
Cancer is the second leading cause of death in the United States, with more than 2 million new

cancer cases and over 626,000 deaths projected for 2026.[1] Guideline-recommended single-

cancer screening is available for only four cancers: breast, cervical, colorectal, and lung.[2-5]

Such screening has resulted in early cancer detection and contributed to improved clinical

outcomes and mortality for these cancer types.[1] However, guideline-recommended single-

cancer screening addresses only about 1/3 of incident cancers and cancer related deaths,[6] with

2/3 lacking recommended screening options.[1] Finally, current single-cancer screening tests

sacrifice specificity to optimize sensitivity, resulting in substantial false positive (FP) rates. The

reported FP rates for guideline-recommended single-cancer screening tests range from 6.0%

for colorectal (age-adjusted mt-sDNA) to 14.5% for cervical (Papanicolaou test) for each round

of screening.[7-10] Since the probability of obtaining a FP result increases with each round of

recommended breast, cervical, colorectal, and lung cancer screening, the cumulative estimated

lifetime FP risk associated with guideline-recommended single-cancer screening is

considerable.[11, 12] To address some of these limitations and improve upon current population-

based single-cancer screening efforts, significant efforts are being made in the development of

early-detection screening strategies that simultaneously detect multiple cancers in a single

blood test.

Advances in sensitive high-throughput technologies and machine learning have led to the

development of minimally invasive, blood-based, single and multi-biomarker class multicancer

early detection (MCED) tests. Several MCED tests are under development to identify multiple

cancers earlier by detecting shared cancer-derived DNA (methylation, fragmentation,

mutations), proteins, or other biomarkers in the blood.[13-19] Since MCED tests interrogate cancer

signals originating from multiple organ systems they represent a potential paradigm shift in

cancer screening, and several assay attributes must be considered to optimize test

development.

First, MCED tests must expand the range of screen detected cancers. Second, MCED tests

must demonstrate sensitivity to detect early-stage cancers, particularly cancers where early-

stage diagnoses enable intervention with curative intent. Third, sensitivity must be balanced with

a relatively high specificity. For MCED tests, this balance aims to maximize potential benefits

(i.e., early-stage detection) while keeping harms from FP results acceptable. These harms may

be further reduced by an efficient diagnostic strategy following a positive MCED test that

minimizes the diagnostic burden for patients.

Sensitivity for early-stage solid tumors, when treatment with curative intent is available, is likely

to have an outsized impact on the benefits of screening with MCED. Notably, in the Detecting

cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A)

trial, the first prospective, interventional study to investigate MCED testing, all eight patients

whose cancers were treated following detection via MCED testing and subsequent diagnosis at

Stage I or II remain alive and cancer-free after >4 years of follow up.[20] While of modest size, this

observation highlights the feasibility of early detection of solid tumors using a multi-biomarker

class MCED test, and provides early evidence that successful treatment can be reliably

delivered. These observations highlight the importance of an emphasis on early-stage sensitivity

in MCED development. [19]

We previously developed a methylation and protein (MP V1) MCED classifier utilizing a

prospectively collected case-control study of individuals aged 50-84, allowing the detection of a

broad range of cancer organ types at all stages.[15] The specificity target for MP V1 was set at a

minimum of ≥98.0%. Subsequent validation using an independent test set confirmed that the

MP V1 classifier achieved the specificity requirement, with observed sensitivities of 15.4%,

38.0%, and 26.1% for stage I, stage II, and stage I and II combined, respectively.[15]

Molecular diagnostic tests, including MCED tests, are often developed using case-control

studies.[21, 22] MCED tests are designed with high specificity targets to limit FP results, and the

performance observed using case-control samples may not accurately represent real-world

performance in a clinical setting.[17, 18, 21, 22] To demonstrate clinical utility, MCED tests must be

designed to detect cancers at early stages when they may be more amenable to curative intent.

In this algorithm development study, we developed an optimized MP classifier architecture (MP

V2) using a lower target specificity (≥97.0%) in a case-control setting to optimize sensitivity for

early-stage cancers. We then validated the classifier performance using an independent testing

set that more closely resembled the intended-use population.

Results

Classifier Selection using an Independent Mini-holdout (MHO) Test Set

MP V1 and MP V2 performance were first examined in MHO classifier selection test set

samples from a previously untested cohort of Ascertaining Serial Cancer patients to Enable

New Diagnostic 2 (ASCEND-2) study subjects (Figure 1). A series of comparisons were

performed to examine changes in target specificity, classifier model architecture, and both

together.

Lowering the specificity target and using the MP V1 classifier

Performance is shown in Table 1 and Supplementary Materials Table S1. At a target specificity

of ≥98%, the MP V1 classifier resulted in a measured specificity of 99.4% (95% confidence

interval [95%CI]: 98.3, 99.8), with an overall sensitivity of 60.9% (95% CI: 51.6, 69.5), and

sensitivities of 31.8% (95% CI:16.4, 52.7), 47.7% (95% CI: 33.8, 62.1), 63.6% (95% CI: 43.0,

80.3), 68.2% (95% CI: 47.3, 83.6), 95.7% (95% CI: 79.0, 99.2), and 42.9% (95% CI: 24.5, 63.5)

for stages I, I and II combined, II, III, IV, and unknown, respectively for the MHO classifier

selection test set (Table 1). When the MP V1 target specificity was lowered to ≥97.0%, the MP

V1 classifier (measured specificity of 99.0%; 95% CI: 97.7, 99.6) demonstrated an overall

sensitivity of 64.5% (95% CI: 55.3, 72.9), and sensitivities of 36.4% (95% CI: 19.7, 57.0), 52.3%

(95% CI: 37.9, 66.2), 68.2% (95% CI: 47.3, 83.6), 77.3% (95% CI: 56.6, 89.9), 95.7% (95% CI:

79.0, 99.2), and 42.9% (95% CI: 24.5, 63.5) for stages I, I and II combined, II, III, IV, and

unknown, respectively for the MHO classifier selection test set (Supplementary Materials Table

S1).

By lowering the MP V1 target specificity by 1% (≥98.0% to ≥97.0%), we observed absolute

sensitivity increases of 3.6%, 4.6%, 4.6%, and 4.6% for overall, stage I, II, and stages I and II

combined, respectively, in the MHO classifier selection test set (Table 1). These sensitivity

increases are equivalent to relative sensitivity increases of 5.9%, 14.5%, 7.2%, and 9.6% for

overall, stage I, II, and stages I and II combined, respectively.

Incorporating improved classifier model architecture and a lower specificity target

The MP V2 classifier at a target specificity of ≥97.0% (measured specificity of 99.0%; 95% CI:

97.7, 99.6) demonstrated an overall sensitivity of 72.7% (95% CI: 63.7, 80.2), and sensitivities

of 40.9% (95% CI: 23.3, 61.3), 56.8% (95% CI: 42.2, 70.3), 72.7% (95% CI: 51.8, 86.8), 86.4%

(95% CI: 66.7, 95.3), 100.0% (95% CI: 85.7, 100.0), and 61.9% (95% CI: 40.9, 79.2) for stages

I, I and II combined, II, III, IV, and unknown, respectively in the MHO classifier selection test set

(Supplementary Materials Table S1).

Evaluating the impact of changes to the specificity target and changes to the model architecture

MP V2 classifier performance (target specificity of ≥97%) was compared to the MP V1 classifier

performance (target specificity of ≥98%). Compared to the MP V1 classifier (measured

specificity of 99.4%), the MP V2 classifier (measured specificity of 99.0%) resulted in absolute

sensitivity increases of 11.8%, 9.1%, 9.1%, and 9.1% for overall, stage I, II, and stages I and II

combined, respectively, in the MHO classifier selection test set (Table 1). These absolute

sensitivity increases are equivalent to relative sensitivity increases of 19.4%, 28.6%, 14.3%, and

19.1% for overall, stage I, II, and stages I and II combined, respectively (Table 1),

Isolating the impact of model architecture evolution

To evaluate the performance contributions that may be attributed to improved MP V2 model

architecture versus a lowered specificity, MP V2 and MP V1 classifier performances were

compared at the same target specificity of ≥97% (measured specificity of 99.0%). Compared to

MP V1, MP V2 demonstrated absolute sensitivity increases of 8.2%, 4.5%, 4.5%, and 4.5% for

overall, stage I, II, and stages I and II combined, respectively, in the MHO classifier selection

test set. These absolute sensitivity increases are equivalent to relative sensitivity increases of

12.7%, 12.4%, 6.6%, and 8.6% for overall, stage I, II, and stages I and II combined, respectively

(Table 1). The performance results above suggest that a substantial portion of the observed

increases in stage I/II sensitivity may be attributed to MP V2 model architecture improvements.

MP V1 and V2 Classifier Test Set Performance Comparison

The locked MP V2 classifier was then evaluated using the original ASCEND-2 test development

set cohort that was used to evaluate the previously reported MP V1 classifier performance

(Figure 1).[15] At a measured specificity of 97.4%, MP V2 demonstrated improvements across all

stage groups compared to MP V1 (specificity 98.5%) (Table 2). Overall sensitivity increased

from 50.9% (MP V1) to 57.8% (MP V2), with stage-specific sensitivity increases of 6.0% for

stage I, 8.0% for stage II, and 6.9% for stage I–II combined. Relative sensitivity increases were

39.0% for stage I, 21.1% for stage II, and 26.4% for stage I–II combined. Detailed results by

stage are shown in Table 2. The differences in absolute sensitivity were statistically significant

by McNemar's test (p < 0.01) for all comparisons except stage IV (p=0.039) and stage unknown

(p=0.125). V2 and V1 methylation sub-models demonstrated similar discrimination (AUROC

0.83 and 0.81, respectively) for this dataset. At equivalent targeted specificity (>97.0%), MP V2

classifier showed improvements compared to MP V1 in early-stage sensitivity (33.0% vs 31.0%)

and specificity (97.4% vs 97.2%), however these results were not statistically significant.

MP V1 and MP V2 classifier performance was also compared using the test development set

with breast and prostate cancers excluded. At a specificity of 97.4%, MP V2 demonstrated

improvements across all stage groups compared to MP V1 (specificity 98.5%) (Table 2). Overall

sensitivity increased from 56.8% (MP V1) to 64.1% (MP V2), with stage-specific improvements

of 7.6% for stage I, 9.2% for stage II, and 8.3% for stage I–II combined. Relative sensitivity

increases were 44.2% for stage I, 18.9% for stage II, and 27.0% for stage I–II combined.

Detailed results by stage are shown in Table 2. The differences in absolute sensitivity were

statistically significant by McNemar's test (p < 0.01) for all comparisons except stage IV

(p=0.070) and stage unknown (p=0.125).

Overall sensitivities by organ type for MP V1 (measured 98.5% specificity) and MP V2

(measured 97.4% specificity) classifiers using the test development set ranged from 11.8% for

prostate to 80.0% for liver and bile duct (Supplementary Materials Figure S2). MP V1 and MP

V2 performance comparisons by organ type and stage are shown in Supplementary Materials

Table S2. MP V2 absolute increase in sensitivity was statistically significant for breast (p-

value=0.016), bladder (p-value=0.031), and colorectal (p-value=0.002) cancers.

MP V2 Independent Clinical Validation Set: Participant Characteristics

MP V2 classifier performance was also evaluated in an independent clinical validation

(N=1,124; 324 cancer and 800 non-cancer) test set consisting of previously untested samples

from the ASCEND-2 study (Figure 1). The clinical validation set consisted of 1,124 subjects with

mean age of 64.8 years; 51.2% were female. 83.7% of the clinical validation cohort identified as

White, 10.8% Black or African American, and 1.1% Asian; 83.6% were of non-Hispanic/Latino

ethnicity. Fifty-three percent were never cigarette smokers, and 50.4% indicated current alcohol

consumption. The mean body mass index was 30.0 kg/m^2, and 56.3% indicated a family history

of cancer in a first-degree relative. Cancer and non-cancer participants had similar age, sex,

and race/ethnicity, body mass index, and cigarette smoking/alcohol consumption distributions

(Table 3). This sample set was selected to more closely resemble the intended use population.

MP V2 Classifier Independent Clinical Validation Set Performance

Using the independent clinical validation set, the MP V2 classifier, at a measured specificity of

97.4% (95% CI: 96.0, 98.3), showed an overall sensitivity of 41.4% (95% CI: 36.1, 46.8), and

sensitivities of 16.0% (95% CI: 10.3, 24.2), 22.8% (95% CI: 17.4, 29.2), 31.3% (95% CI: 22.4,

41.9), 52.9% (95% CI: 41.3, 64.1), and 83.1% (95% CI: 72.2, 90.3) for stages I, I and II

combined, II, III, and IV, respectively (Table 4). Overall sensitivity excluding cancer organ types

with average-risk, single-cancer screening (i.e. excluding breast, prostate, cervix, colon and

rectum) was 52.4% (95% CI: 43.7, 60.9) and 67.9% (95% CI: 58.5, 76.0) for the six most

aggressive cancer organ types with the shortest 5-year survival rate (i.e. pancreas, esophagus,

liver, lung and bronchus, stomach, and ovary).[23] With breast and prostate cancers excluded, the

MP V2 classifier demonstrated an overall sensitivity of 55.6% (95% CI: 49.0, 62.0), and

sensitivities of 26.8% (95% CI: 17.0, 39.6), 34.8% (95% CI: 26.6, 44.0), 42.9% (95% CI: 30.8,

55.9), 63.6% (95% CI: 50.4, 75.1), and 89.3% (95% CI: 78.5, 95.0) for stages I, I and II

combined, II, III, and IV, respectively (Table 4). The MP V2 classifier overall sensitivities by

organ type ranged from 3.9% (prostate) to 100.0% (ovary, small intestine, anus, vulva, and

testis) (Supplementary Materials Table S4) in the clinical validation set. Table S4 also shows the

performance by stage.

Cancer Subtype Analysis

The MP test is based on sets of shared methylation and protein biomarkers present in many

different tumor types; these biomarkers have the potential to detect a broad range of cancers

from a blood specimen. The case report forms obtained from 635 subjects with cancer (421

from the MP V2 test development set, 80 from the MHO test set, and 134 from the independent

clinical validation test set) were assessed to determine the tumor types and histological

subtypes detected. Over fifty distinct cancer subtypes were identified. Among those, 17 cancer

subtypes were identified based on single cases (n=1). Cancer subtype staging was not

determined. The cancer subtypes detected are listed in Supplementary Materials Table S5.

Discussion

MCED testing has the potential to shift population-wide cancer screening from single-cancer

screening of a handful of cancers to many cancers through expanded multi-cancer screening

using a single blood specimen. MCED tests are typically designed with high specificity targets to

limit FP results and the associated harms associated with futile diagnostic procedures.[24]

Classifier development is challenging as it requires balancing case-control derived

sensitivity/specificity measurements to project real world-clinical performance. We therefore

attempted to develop a refined classifier that is more generalizable to cohort differences and

target a lower target specificity in a case-control setting. In this study, we first identified and

selected a new model architecture and then adjusted the specificity target to evaluate

performance in a classifier selection set, a previously described test set, and finally in an

independent validation set more closely representative of the intended use population. We

found that incorporating MP V2 model architecture improvements and lowering the specificity

target by one percent resulted in a 6.9% absolute (26.4% relative) sensitivity increase for early-

stage cancers (stage I and II combined) compared to the MP V1 classifier. A detailed analysis of

the MHO classifier selection set showed that the observed performance improvements are due

to both the lower case-control target specificity and the new model architecture. The MP V2

classifier will be utilized in a real-world setting to further validate the sensitivity and specificity

results.

False positive results are of concern for both single cancer and MCED tests. However, since

MCED tests interrogate cancer signals originating from multiple organ sites, FP MCED results

could trigger diagnostic procedures that may impose physical and psychological burdens on

patients to definitively rule in or rule out cancer. Specificities of ≥98.9% have been reported for

the prospective PATHFINDER, PATHFINDER-2, and DETECT-A studies, resulting in FP rates

of ≤2%,[17, 18, 19] much lower than FP rates reported for guideline-recommended single-cancer

screening tests.[12] An invasive procedure (e.g., surgery) was required to resolve FP results in

just 2%, 0.4%, and 3% of cases, respectively in the aforementioned studies.[17, 18, 19] Efficient

imaging-based diagnostic resolution strategies may further reduce the potential risks associated

with the workup for FP MCED test results.[25]

This study has some limitations. Of the projected two million new cancer diagnoses in 2026,[1] it

is estimated that approximately 88% (almost 1.8 million) will occur in individuals aged 50 years

and older.[26] In addition, it is likely that the prevalence of undiagnosed cancers harbored by

apparently healthy individuals at any point in time is higher as many cancers have pre-clinical

dwell times that extend beyond one year.[27] The controls used to develop and test the MP V1

classifier included age-matched individuals without suspicion of cancer. While free from

suspicion of cancer at the time of enrollment, controls were not required to have completed all

recommended cancer screening tests, were not subject to any procedures to rule out the

presence of an occult cancer and participants were not followed after contributing a blood

sample to confirm the absence of cancer that might emerge in subsequent months. Therefore,

the control group likely included individuals with hidden, undiagnosed cancers. Thus, targeting a

specificity of ≥98.5% in the MP V1 classifier development case-control study may have been

conservative, given that measured specificity was likely slightly underestimated by undiagnosed

cancers in the control group, potentially sacrificing sensitivity.

Although the ASCEND-2 samples used in this study were prospectively collected from more

than 200 sites across the US and Europe and included a diverse participant cohort broadly

representative of the U.S. population, the analyses were performed with cases having tumor

type representation that is close to an intended use population but with equal stage distributions

across several cancer types. Therefore, the ASCEND -2 case-control performance results might

be different than real-world test performance. Both the MP V1 and MP V2 classifiers were

evaluated using the same test set design. When MP V2 classifier sensitivity was assessed in a

clinical validation cohort that more closely reflected SEER incidence, the observed overall

sensitivity was 41.4%. MCED test performance must be interpreted with considerable caution,

as differences in cancer types/stages affect performance estimates. Previous studies have

reported significant differences in performance between case-control and prospective

interventional studies,[17-19, 21, 22] even for the same assay in different prospective studies.[18, 19]

While improvements in performance due to test development can be assessed in case-control

studies, as reported here, performance in the screening setting is determined in prospective

studies in the intended-use population. Therefore, performance comparisons across studies

should account for differences in design, cancer type mix, and stage distribution, and simple

cross-study comparisons should be avoided.

In summary, as part of an ongoing MCED test development process, we trained and tested a

refined MCED classifier, MP V2. We adjusted a pre-specified case-control specificity target from

≥98% to ≥97% to optimize early-stage (stages I and II) cancer detection which should result in

maintained or increased specificity in a real-world setting.[17, 18, 21, 22] The locked MP V2 classifier

was then evaluated in a clinical validation cohort selected to more closely resemble a real-world

population. Prospective, real-world evaluation of the MP V2 classifier will be needed to

determine if we achieved the optimal balance between sensitivity and specificity.

Methods

MP V1 Classifier

A prospectively collected, case-control study, ASCEND-2, was the primary sample source for

the development of the MP V1 classifier.[15] MP V1 classifier development included participants

from multiple sites across the United States and within Europe. The MP V1 classifier

development cohort included male and female subjects ≥50 years old with known cancer and

controls without suspicion of cancer. Cases were recruited immediately following cancer

diagnosis and before treatment initiation or, in the case of cancer types that are diagnosed with

excisional biopsies, immediately prior to the diagnostic and therapeutic procedure. All collection

sites had Institutional Review Board approval, and all eligible subjects provided written informed

consent and were assessed for study participation eligibility. Blood samples were collected in

LBgard® tubes at the study sites, shipped to centralized laboratories, and processed into plasma

and buffy aliquots. Protein and methylation assays were assessed using separate plasma

aliquots.

Protein Analysis

Plasma protein concentrations were measured using commercially available assays for 6

proteins on a Roche cobas e801 instrument (Roche Diagnostics, Indianapolis, IN) per

manufacturer's recommendations.[28] The cobas e801 analyzer uses electrochemiluminescence

(ECL)-based immunoassays to measure protein concentrations.

Methylated DNA Marker (MDM) Analysis

Methylated DNA markers were measured as previously described.[28] Briefly, circulating tumor

(ctDNA) was extracted from 6 mL plasma followed by bisulfite conversion on a Hamilton

Microlab STARlet (Hamilton Robotics, Reno, NV) using reagents manufactured by Exact

Sciences Corporation (Madison, WI). Bisulfite converted ctDNA was then analyzed using Target

Enrichment Long-probe Quantitative Amplified Signal (TELQAS™) chemistry. For the initial

target enrichment, converted ctDNA was transferred to a 96-well polymerase chain reaction

(PCR) plate and subjected to multiplex PCR to amplify the MDMs and a reference methylation

marker. The PCR products were diluted 10-fold and evaluated in triplex or biplex assays using

Long-probe Quantitative Amplified Signal (LQAS™) on a Quantstudio 5 Dx Real-Time PCR

Instrument (Life Technologies Corporation, Grand Island, NY). TELQAS combines amplification

using real-time PCR and allele-specific detection of methylated target DNA through an invasive

cleavage assay.

MP V2 Classifier Training

The overall MP V2 classifier development workflow is shown in Figure 1. The MP V2 classifier

candidates were trained using the same methylation and protein data set previously used for the

training of MP V1[15]. The total training set was comprised of 3,027 samples (654 cancer and

2,373 non-cancer), that was partitioned into two sub-groups for 5-fold cross validation (N=1,819;

431 cancer and 1,388 non-cancer) and MHO testing (N=1,208; 223 cancer and 985 non-

cancer). The MP V2 training set was used to investigate multiple alternative classifier

architectures, feature engineering, and transformation approaches as well as to perform tuning

of specificity thresholds. A target specificity of ≥97.0% was used for MP V2 classifier training.

Only samples that passed pre-specified methylation and protein assay quality control criteria

were included in the training process; these criteria were identical for the MP V1 and MP V2

training processes. Methylation and protein classifiers were trained individually, and the

individual classifier results were combined using a logical OR overarching classifier to generate

the final (positive or negative) call. The result was deemed positive when either the methylation

or protein assay provided a cancer signal detected call.

MP V2 Classifier Model Selection

After multiple potential classifiers were developed and evaluated as part of training, locked

candidate models were compared during a classifier selection step using newly generated

methylation and protein data from an independent MHO classifier selection test set (MHO;

n=619; n=110 Cancers; n=509 non-cancers). The samples were selected from a previously

untested cohort of subjects of the ASCEND-2 study cohort.[15] The performance of the MP V2

candidate classifiers was compared to the MP V1 classifier at two different target specificities

(original target of ≥98.0% and updated target of ≥97.0%). A Feature Weighted Naive Bayes

(FWNB) classifier was selected as it showed improved performance compared to both MP V1

and other candidate MP V2 model architectures. This model was locked for additional tuning

and then subjected to additional testing.

MP V2 Classifier Evaluation

To enable direct comparison of V2 to V1 MP classifiers, the locked MP V2 classifier was tested

using the original data set used for the performance characterization of the MP V1 classifier.[15]

This test set included (n=3,163; 729 cancers and 2,434 non-cancers) and was described above.

The MP V2 performance assessment at the adjusted specificity target (≥97%) was compared to

the MP V1 classifier at the original (≥98%) specificity target.

MP V2 Classifier Clinical Validation

The MP V2 classifier performance was further evaluated in an independent clinical validation

(N=1,124; 324 cancer and 800 non-cancer) test set. The samples for this set were selected

from previously untested subjects of the ASCEND-2 study cohort.[15] The clinical validation test

set cancer cohort included nineteen organ sites (prostate (n=51), breast (n=50), lung and

bronchus (n=57), colon and rectal (n=38), kidney (n=19), uterus (n=17), head and neck

(squamous cell; n=17), pancreas (n=17), bladder and urinary (n=12), liver (n=12), thyroid (n=5),

stomach (n=7), ovary (n=7), esophagus (n=6), small intestine (n=3), cervix uteri (n=2), anus

(n=2), vulva (n=1) and testis (n=1)). The stage distributions for these organ tumor sites are

shown in Supplementary Materials Table S3.

Cancer samples were selected to achieve balanced representation across stages I-IV

(excluding breast and prostate cancer) for estimation of stage-specific performance. Within

stage, the distribution of seventeen organ sites (excluding breast and prostate) was chosen to

reflect 2021 incidence reported by the SEER database.[23] For breast and prostate cancer, we

selected fifty samples each, ensuring the stage distribution reflected 2021 SEER incidence.

Non-cancer samples were chosen so that the distribution of age groups, sex, and race mirrored

the demographics reported in the 2021 Census, to more closely represent the intended use

population in a real-world setting.[29] The clinical validation participant demographics and clinical

characteristics are shown in Table 3.

Statistical Analysis

Sensitivity and specificity were estimated overall and stratified by cancer stage. Sensitivity was

defined as the proportion of participants with disease who tested positive, and specificity as the

proportion of participants without disease who tested negative. Two-sided 95% confidence

intervals were calculated using the Wilson score method. Comparisons of sensitivity and

specificity between classifiers were performed using McNemar's test for paired binary

outcomes, applied within each stage group and for the overall cohort. Statistical significance

was assessed using two-sided tests with a threshold of $p < 0.05$. SAS software

(https://www.sas.com) was used for CV analysis, Python SciPy and statsmodels

(https://www.statsmodels.org), scikit-learn (https://www.scikit-learn.org) was used for model

development.

Cancer Subtype Analysis

Case report forms were assessed by three independent physicians to identify biopsy and

histopathology variables for each detected tumor type across the cohorts. The cancers were

classified into distinct histological types and subtypes based on cancer site, morphology, and

international classification of diseases for oncology (ICD-O) codes. Certain cancer types were

designated as unique due to differences in histology, pathogenesis, risk factors, and clinical

management, reflecting their recognition as separate entities in clinical practice. Limited cancer

type, histology subtype, and clinical information were available for this analysis, and certain

histological subtypes were not classified as distinct cancer types. With limited numbers of cases

that represent many cancer subtypes, these data should not be used to estimate real world test

performance by cancer subtypes.

Data Availability

The data generated in this study is available upon request from the corresponding author.

Acknowledgements

The authors would like to thank Michelle Beidelschies for leadership and feedback. Carolyn Hall and Feyza Sancar (Exact Sciences Corporation, Madison, WI) provided manuscript writing and editorial support. The authors would also like to thank the patients who generously participated in the original sample collection studies and the principal investigators and institutions who oversaw their enrollment. This study was funded by Exact Sciences Corporation.

Author Contributions

Conceptualization: Frank Diehl

Methodology: Vladimir Gainullin, Frank Diehl

Formal Analysis: Vladimir Gainullin, Melissa Gray, Madhav Kumar, Stephen Luebker, Amy Lehman, Omair Choudhry, Julia Roberta, Darl Flake, Avinash Shanmugam, Kevin Cortes, Emily Chang, Philip J. Uren

Writing-Original Draft: Vladimir Gainullin, Frank Diehl, Tomasz M. Beer

Writing-Review and Editing: Vladimir Gainullin, Melissa Gray, Madhav Kumar, Stephen Luebker, Amy Lehman, Omair Choudhry, Julia Roberta, Darl Flake, Avinash Shanmugam, Kevin Cortes, Emily Chang, Philip J. Uren, Amin Mazloom, Jorge Garces, Tomasz M. Beer, Frank Diehl

Project Administration: Amin Mazloom, Jorge Garces, Frank Diehl

Conflicts of Interest

V.G.G., **M.G.**, **M.K., S.L., A.M.L., O.A.C., J.R., D.D.F. II, A.S., K.C., E.C., P.J.U., J.G., A.M., T.M.B.**, and **F.D.** are employees at Exact Sciences Corporation and declare stock ownership at Exact Sciences Corporation. **A.M., J.G.**, **T.M.B.**, and **F.D.** hold leadership roles at Exact Sciences Corporation. **P.J.U.** declares stock ownership at Biora Therapeutics outside this work.

T.M.B. declares stock ownership at Osteologic and Osheru, and a consulting/advisory role at

AstraZeneca outside this work. **G.A.S.** declares advisory board service at Candel Therapeutics,

consulting fees from Freenome and Biodesix, and research funding (Institutional) from NIH

(RO1 screening in frail populations), Nucleix, Inc, Biodesix, Delfi Diagnostics, and Freenome

outside this work. **G.A.S.** serves on the American Cancer Society roundtable steering

committee outside this work. **D.W.C.** declares no conflicts of interest. **R.W.G.** declares

speaker's bureau service at Bayer and Johnson & Johnson, research funding from Francis

Medical, MDX Health, Levee, and Dendreon; and travel reimbursement from Francis Medical

outside this work.

460
461 **References**
462

1   Siegel RL, Kratzer TB, Wagle NS et al. Cancer statistics, 2026. CA: A Cancer Journal for

Clinicians 2026; 76 (1): e70043.

2   Curry SJ, Krist AH, Owens DK et al. Screening for Cervical Cancer: US Preventive

Services Task Force Recommendation Statement. JAMA 2018; 320 (7): 674-686.

3   Davidson KW, Barry MJ, Mangione CM et al. Screening for Colorectal Cancer: US

Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19):

1965-1977.

4   Potter AL, Bajaj SS, Yang CJ. The 2021 USPSTF lung cancer screening guidelines: a

new frontier. Lancet Respir Med 2021; 9 (7): 689-691.

5   Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force

Recommendation Statement. Ann Intern Med 2016; 164 (4): 279-296.

6   NORC (University of Chicago). Only 14% of Cancers Are Detected Through a

Preventive Screening Test.; 2022. https://www.norc.org/content/dam/norc-

org/pdfs/State-Specific%20PCDSs%20chart%201213.pdf

477 7 Imperiale TF, Porter K, Limburg PJ. Stool and Blood DNA Tests for Colorectal Cancer

478   Screening. Reply. N Engl J Med 2024; 390 (23): 2225.

479 8 Kim JJ, Burger EA, Regan C et al. Screening for Cervical Cancer in Primary Care: A

480   Decision Analysis for the US Preventive Services Task Force. JAMA 2018; 320 (7): 706-

481   714.

482 9 Lehman CD, Arao RF, Sprague BL et al. National Performance Benchmarks for Modern

483   Screening Digital Mammography: Update from the Breast Cancer Surveillance

484   Consortium. Radiology 2017; 283 (1): 49-58.

485 10 Pinsky PF, Gierada DS, Black W et al. Performance of Lung-RADS in the National Lung

486   Screening Trial: a retrospective assessment. Ann Intern Med 2015; 162 (7): 485-491.

487 11 Braunstein GD, Ofman JJ. Criteria for evaluating multi-cancer early detection tests.

488   2021.

489 12 White T, Algeri S. Estimating the lifetime risk of a false positive screening test result.

490   PLOS ONE 2023; 18 (2): e0281153.

491 13 Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using

492   multidimensional cell-free DNA fragmentomics. Nat Med 2025.

493 14 Gainullin V, Bae J, Guthrie VB et al. Abstract A056: Performance of multi-biomarker

494   class reflex testing in a prospectively-collected cohort. Clinical Cancer Research 2024;

495   30 (21_Supplement): A056-A056.

496 15 Gainullin V, Manesse M, Zhuang F et al. Performance of a multi-target, multi-cancer

497   early detection (MCED) blood test in a prospectively collected cohort. medRxiv 2025:

498   2025.2008.2024.25334244.

499 16 Gao Q, Lin YP, Li BS et al. Unintrusive multi-cancer detection by circulating cell-free

500   DNA methylation sequencing (THUNDER): development and independent validation

501   studies. Ann Oncol 2023.

Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020; 369 (6499): eabb9601.

Schrag D, Beer TM, McDonnell CH, 3rd et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 2023; 402 (10409): 1251-1260.

Nabavizadeh N, McDonnell C, III, Kurbegov D et al. LBA64 Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: Initial results from the registrational PATHFINDER II study. Annals of Oncology 2025; 36: S1720.

Buchanan AH, Lennon AM, Choudhry OA et al. Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test. Cancer Prev Res (Phila) 2024; 17 (8): 349-353.

Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; 359 (6378): 926-930.

Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 2021; 32 (9): 1167-1177.

SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute (2023). [Accessed March 4, 2025]. https://seer.cancer.gov/statistics-network/explorer/

Kisiel JB, Ebbert JO, Taylor WR et al. Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing. Life 2024; 14 (8): 925.

Tyson C, Li KH, Cao X et al. Tumor localization strategies of multi-cancer early detection tests: a quantitative assessment. JNCI Cancer Spectrum 2025.

American Cancer Society. Cancer Facts and Figures, 2023. Atlanta, GA: American Cancer Society. [Accessed March 4, 2025]. https://www.cancer.org/content/dam/cancer-

org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-

cancer-facts-and-figures.pdf

27   Chhatwal J, ElHabr A, Tyson C et al. Correlation of unobserved incidence of cancer in

earlier stages with the observed incidence. Journal of Clinical Oncology 2023; 41

(16_suppl): 10634-10634.

28   Katerov VE, Fleming HL, Rugowski DE et al. The detection of multiple cancer types with

an extended set of methylation and protein markers. Journal of Clinical Oncology 2023;

41 (16_suppl): 3040-3040.

29   U.S. Census Bureau 2020. Profile of General Population and Housing Characteristics.

Accessed May 2, 2025].

https://data.census.gov/table?g=010XX00US&d=DEC+Demographic+Profile

555   Table 1. Independent mini-holdout classifier selection test set performance comparison

	MP V1 Classifier Target specificity ≥98.0% (95% CI), n/N	MP V1 Classifier Target specificity ≥97.0% (95% CI), n/N		MP V2 Classifier Target specificity ≥97.0% (95% CI), n/N		MP V2 Classifier Target specificity ≥97.0% (95% CI), n/N	
Measured Specificity	99.4% (98.3, 99.8), 506/509	99.0% (97.7, 99.6), 504/509		99.0% (97.7, 99.6), 504/509		99.0% (97.7, 99.6), 504/509	
		Versus MP V1 classifier @ ≥98% Target Specificity		Versus MP V1 classifier @ ≥98% Target Specificity		Versus MP V1 classifier @ ≥97% Target Specificity	
		Absolute Increase*	Relative Increase**	Absolute Increase*	Relative Increase**	Absolute Increase*	Relative Increase**
Overall Sensitivity	60.9% (51.6, 69.5), 67/110	3.6%	5.9%	11.8%	19.4%	8.2%	12.7%
Sensitivity by Stage:							
Stage I	31.8% (16.4, 52.7), 7/22	4.6%	14.5%	9.1%	28.6%	4.5%	12.4%
Stage II	63.6% (43.0, 80.3), 14/22	4.6%	7.2%	9.1%	14.3%	4.5%	6.6%
Stage III	68.2% (47.3, 83.6), 15/22	9.1%	13.3%	18.2%	26.7%	9.1%	11.8%
Stage IV	95.7% (79.0, 99.2), 22/23	0.0%	0.0%	4.3%	4.5%	4.3%	4.5%
Unknown	42.9% (24.5, 63.5), 9/21	0.0%	0.0%	19.0%	44.3%	19.0%	44.3%
Stages I-II	47.7% (33.8, 62.1), 21/44	4.6%	9.6%	9.1%	19.1%	4.5%	8.6%

557   *Absolute Increase=Sensitivity B% - Sensitivity A%. ** Relative Increase=Sensitivity B% –
558   Sensitivity A%/Sensitivity A% x 100.

572   Table 2. MP V1 and V2 classifier performance in the test set

	MP V1 Classifier Performance (95% CI)	MP V2 Classifier Performance (95% CI)	p-value ‡	MP V2 Classifier Versus MP V1 Classifier[a]	
Specificity (n=2,434)	98.5% (97.9, 98.9)	97.4% (96.7, 97.9)	<0.0001 ****	Absolute Increase[b]	Relative Increase[c]
Overall Sensitivity, all cancers (n=729)	50.9% (47.3, 54.5)	57.8% (54.1, 61.3)	<0.0001 ****	6.9%	13.6%
Stage I (n=182)	15.4% (10.9, 21.3)	21.4% (16.1, 27.9)	0.003 **	6.0%	39.0%
Stage II (n=163)	38.0% (30.9, 45.7)	46.0% (38.5, 53.7)	0.00024 ***	8.0%	21.1%
Stage III (n=180)	67.8% (60.6, 74.2)	76.1% (69.4, 81.8)	<0.0001 ****	8.3%	12.2%
Stage IV (n=172)	85.5% (79.4, 90.0)	89.5% (84.1, 93.3)	0.039 *	4.0%	4.7%
Unknown Stage (n=32)	37.5% (22.9, 54.7)	50.0% (33.6, 66.4)	0.125 n.s.	12.5%	33.3%
Stages I/II (n=345)	26.1% (21.7, 31.0)	33.0% (28.3, 38.2)	<0.0001 ****	6.9%	26.4%
Overall Sensitivity, breast and prostate cancers excluded (n=590)	56.8% (52.8, 60.7)	64.1% (60.1, 67.8)	<0.0001 ****	7.3%	12.9%
Stage I (n=145)	17.2% (12.0, 24.2)	24.8% (18.5, 32.4)	0.003 **	7.6%	44.2%
Stage II (n=109)	48.6% (39.4, 57.9)	57.8% (48.4, 66.6)	0.002 **	9.2%	18.9%
Stage III (n=151)	73.5% (66.0, 79.9)	81.5% (74.5, 86.8)	0.00049 ***	8.0%	10.9%
Stage IV (n=155)	86.5% (80.2, 91.0)	90.3% (84.6, 94.0)	0.070 n.s.	3.8%	4.4%
Unknown Stage (n=30)	40.0% (24.6, 57.7)	53.3% (36.1, 69.8)	0.125 n.s.	13.3%	33.3%
Stages I/II (n=254)	30.7% (25.4, 36.6)	39.0% (33.2, 45.1)	<0.0001 ****	8.3%	27.0%
Overall Sensitivity[d]	54.8% (50.4, 59.2)	61.6% (57.2, 65.8)	<0.0001 ****	6.8%	12.4%
Overall Sensitivity[e]	63.7% (58.0, 69.0)	67.8% (62.2, 72.9)	0.002**	4.1%	6.4%

[a]MP V2 classifier (97.4% specificity) versus an MP V1 classifier (98.5% specificity). [b]Absolute
Increase=Sensitivity MP V2% - Sensitivity MP V1%. [c]Relative Increase=Sensitivity MP V2% –
Sensitivity MP V1%/Sensitivity MP V1% x 100. [d]Sensitivity excluding cancer organ types with
average-risk standard of care screening (i.e., excluding breast, prostate, cervix, colon and
rectum). [e]Sensitivity for the 6 most aggressive cancer organ types with the shortest 5-year
survival rate reported by National Cancer Institute Surveillance, Epidemiology, and End Results
(SEER) (i.e., pancreas, esophagus, liver, lung and bronchus, stomach, and ovary). ‡, McNemar
test; n.s., not significant; *, significant; **moderately significant; ***very significant; **** highly
significant.

 Table 3. MP V2 clinical validation set participant demographics and clinical characteristics

	Characteristic	Cancer n (%)	Non-Cancer n (%)	Total N (%)
Sex	Female	160 (49.4%)	415 (51.9%)	575 (51.2%)
.	Male	164 (50.6%)	385 (48.1%)	549 (48.8%)
Age (years)	Mean (SD)	66.9 (8.2)	63.7 (8.9)	64.6 (8.8)
.	(Min, Max)	(50, 84)	(50, 84)	(50, 84)
Race	White	284 (87.7%)	657 (82.1%)	941 (83.7%)
.	Black or African American	30 (9.3%)	91 (11.4%)	121 (10.8%)
	Asian	2 (0.6%)	10 (1.3%)	12 (1.1%)
	American Indian or Alaska Native	2 (0.6%)	6 (0.8%)	8 (0.7%)
	Native Hawaiian or Other Pacific Islander	1 (0.3%)	1 (0.1%)	2 (0.2%)
	More than one race	1 (0.3%)	6 (0.8%)	7 (0.6%)
	Unknown	4 (1.2%)	29 (3.6%)	33 (2.9%)
Ethnicity	Hispanic/Latino	11 (3.4%)	155 (19.4%)	166 (14.8%)
.	Not Hispanic/Latino	302 (93.2%)	636 (79.5%)	938 (83.6%)
	Unknown	11 (3.4%)	7 (0.9%)	18 (1.6%)
	Missing	0	2	2
BMI (kg/m^2)	Mean (SD)	29.4 (7.1)	30.2 (6.7)	30.0 (6.8)
.	(Min, Max)	(14.2, 61)	(16.4, 66.4)	(14.2, 66.4)
	Missing	1	0	1
Cigarette .Smoking History	Current	50 (15.5%)	118 (14.8%)	168 (15.0%)
	Former	141 (43.8%)	215 (26.9%)	356 (31.7%)
	Never	131 (40.7%)	467 (58.4%)	598 (53.3%)
	Missing	2	0	2

Alcohol Consumption History	Current	153 (47.5%)	411 (51.6%)	564 (50.4%)
	Former	55 (17.1%)	95 (11.9%)	150 (13.4%)
	Never	114 (35.4%)	291 (36.5%)	405 (36.2%)
	Missing	2	3	5
Family History of Cancer in 1st Degree Relative	No	105 (32.4%)	363 (45.4%)	468 (41.7%)
	Yes	208 (64.2%)	424 (53.1%)	632 (56.3%)
	Unknown	11 (3.4%)	12 (1.5%)	23 (2.0%)
	Missing	0	1	1

587   BMI, body mass index kg/m^2

606   Table 4. MP V2 classifier validation set performance

(n/N)	Performance	95% CI
Specificity (779/800)	97.4%	(96.0, 98.3)
Overall Sensitivity, all cancers (134/324)	41.4%	(36.1, 46.8)
Stage I (17/106)	16.0%	(10.3, 24.2)
Stage II (26/83)	31.3%	(22.4, 41.9)
Stage III (37/70)	52.9%	(41.3, 64.1)
Stage IV (54/65)	83.1%	(72.2, 90.3)
Stages I-II (43/189)	22.8%	(17.4, 29.2)
Overall Sensitivity, breast and prostate cancers excluded (124/233)	55.6%	(49.0%, 62.0)
Stage I (15/56)	26.8%	(17.0, 39.6)
Stage II (24/56)	42.9%	(30.8, 55.9)
Stage III (35/55)	63.6%	(50.4, 75.1)
Stage IV (50/56)	89.3%	(78.5, 95.0)
Stages I-II (39/112)	34.8%	(26.6%, 44.0)
Overall Sensitivity* (66/126)	52.4%	(43.7, 60.9)
Overall Sensitivity** (72/106)	67.9%	(58.5, 76.0)

607   *Sensitivity excluding cancer organ types with average-risk standard of care screening (i.e.,
608   excluding breast, prostate, cervix, colon and rectum). **Sensitivity for the 6 most aggressive
609   cancer organ types with the shortest 5-year survival rate reported by National Cancer Institute
610   Surveillance, Epidemiology, and End Results (SEER) (i.e., pancreas, esophagus, liver, lung and
611   bronchus, stomach, and ovary).
612
613
614
615

616   Figure 1. MP V2 classifier development workflow

620   MP, Methylation-Protein.